Gregory R. Friberg - 30 Sep 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief R&D Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
30 Sep 2024
Net transactions value
$0
Form type
4
Filing time
01 Oct 2024, 16:51:26 UTC
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +21,190 $0.000000 21,190 30 Sep 2024 Direct F1
transaction BMRN Common Stock Award $0 +7,870 +37% $0.000000 29,060 30 Sep 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Award $0 +49,850 $0.000000 49,850 30 Sep 2024 Common Stock 49,850 $70.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on September 30, 2024. Price not applicable.
F2 Option grant vests 12/48th on September 30, 2025 and 1/48th per month thereafter.